Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Successful use of zanubrutinib for R/R MCL in China

Yuqin Song • 31 Jan 2019
ASH 2018
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Zanubrutinib

Yuqin Song, PhD, of Peking University Cancer Hospital & Institute, Beijing, China, discusses the promising results of a Phase II trial investigating the efficacy and safety of the BTK inhibitor zanubrutinib in relapsed/refractory mantle cell lymphoma (NCT03206970). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Song describes the best overall response rate for zanubrutinib as 84%, with adverse events generally being grade I or II.

More from Yuqin Song

2:42
Tislelizumab for R/R classical Hodgkin lymphoma
Yuqin Song • 31 Jan 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals